February 11, 2025 Novartis buys Blackstone's Anthos for up to $3.1 billion Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...
Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a ...
Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
As of 10:08:11 AM EDT. Market Open. On Wednesday, Novartis AG (NYSE:NVS) announced safety and efficacy results from the Phase 3 program for investigational intrathecal onasemnogene abeparvovec ...
Effective Jan. 1, 2025, comanager Stephen Sullens stepped down from Blackstone Alternative Multi-Strategy and retired from the industry. On the same day, Stephen Zhu, managing director of ...
Ranked by Number of employees in Georgia dedicated to FinTech Showcase your company news with guaranteed exposure both in print and online Innovation Awards will honor individuals, teams and ...
Over my forty years or so in and around dealing rooms and financial markets, I have heard many theories as to how to approach that problem and have settled on a process that has worked for me ...
Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback